BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 9722072)

  • 1. Differential growth patterns in SCID mice of patient-derived chronic myelogenous leukemias.
    McGuirk J; Yan Y; Childs B; Fernandez J; Barnett L; Jagiello C; Collins N; O'Reilly RJ
    Bone Marrow Transplant; 1998 Aug; 22(4):367-74. PubMed ID: 9722072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase.
    Beran M; Pisa P; O'Brien S; Kurzrock R; Siciliano M; Cork A; Andersson BS; Kohli V; Kantarjian H
    Cancer Res; 1993 Aug; 53(15):3603-10. PubMed ID: 8339266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
    Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
    Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
    Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
    Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology.
    Dazzi F; Capelli D; Hasserjian R; Cotter F; Corbo M; Poletti A; Chinswangwatanakul W; Goldman JM; Gordon MY
    Blood; 1998 Aug; 92(4):1390-6. PubMed ID: 9694728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The severe combined immunodeficient (SCID) mouse as a model for human myeloid leukemias.
    Cesano A; Hoxie JA; Lange B; Nowell PC; Bishop J; Santoli D
    Oncogene; 1992 May; 7(5):827-36. PubMed ID: 1570153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Experimental systems in CML biology].
    Maru Y
    Nihon Rinsho; 2001 Dec; 59(12):2322-8. PubMed ID: 11766333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer cell depletion by anti-asialo GM1 antiserum treatment enhances human hematopoietic stem cell engraftment in NOD/Shi-scid mice.
    Yoshino H; Ueda T; Kawahata M; Kobayashi K; Ebihara Y; Manabe A; Tanaka R; Ito M; Asano S; Nakahata T; Tsuji K
    Bone Marrow Transplant; 2000 Dec; 26(11):1211-6. PubMed ID: 11149733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and characterization of an STI571-resistant human myelogenous leukemia cell line, SR-1.
    Kwon HC; Kim SH; Kim JS; Han H; Roh MS; Han JY; Seo SY; Lee YH; Kim HJ
    Cancer Genet Cytogenet; 2004 Oct; 154(1):52-6. PubMed ID: 15381372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haploinsufficiency and acquired loss of Bcl11b and H2AX induces blast crisis of chronic myelogenous leukemia in a transgenic mouse model.
    Nagamachi A; Yamasaki N; Miyazaki K; Oda H; Miyazaki M; Honda Z; Kominami R; Inaba T; Honda H
    Cancer Sci; 2009 Jul; 100(7):1219-26. PubMed ID: 19432895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
    Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
    Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
    Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent antileukemic activity of the novel agents norsegoline and dibezine.
    Einat M; Nagler A; Lishner M; Amiel A; Yarkoni S; Rudi A; Gellerman G; Kashman Y; Fabian I
    Clin Cancer Res; 1995 Aug; 1(8):823-9. PubMed ID: 9816051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease.
    Krauth MT; Simonitsch I; Aichberger KJ; Mayerhofer M; Sperr WR; Sillaber C; Schneeweiss B; Mann G; Gadner H; Valent P
    Am J Clin Pathol; 2004 Apr; 121(4):473-81. PubMed ID: 15080298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
    Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA
    Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multilineage outgrowth of both malignant and normal hemopoietic progenitor cells from individual chronic myeloid leukemia patients in immunodeficient mice.
    Verstegen MM; Cornelissen JJ; Terpstra W; Wagemaker G; Wognum AW
    Leukemia; 1999 Apr; 13(4):618-28. PubMed ID: 10214871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
    Flavell DJ; Warnes SL; Noss AL; Flavell SU
    Br J Cancer; 2000 Dec; 83(12):1755-61. PubMed ID: 11104577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated and blastic phases of chronic myelogenous leukemia.
    Giles FJ; Cortes JE; Kantarjian HM; O'Brien SM
    Hematol Oncol Clin North Am; 2004 Jun; 18(3):753-74, xii. PubMed ID: 15271404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.